Biogen to Spin Off Multi-Million-Dollar Hemophilia Biz

The new company will focus on the discovery and development of hemophilia therapies, with existing marketed products to include ELOCTATE and ALPROLIX, which had combined revenues of $640M during the last 12-month period
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news